Tests radiation to remaining lung cancer spots alongside osimertinib
Tests added local radiation with osimertinib in adults with EGFR-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 2
Where in Hong Kong
- Department of Clinical Oncology, Prince of Wales HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07379476
- Record updated
- 12 February 2026
- Original description
This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.Read full original descriptionShow less
ATOM2: A Randomized Phase II Trial on Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer After Osimertinib Treatment
This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.
Inclusion: 18 years of age or older and able to understand and give written informed consent; Pathologically proven non-small cell lung cancer; Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing); Stage IV disease; Receive first line osimertinib monotherapy for stage IV disease; Undergo a PET-CT scan after 12-24 weeks of initiation of osimertinib treatment, with no evidence of disease progression, and less than or equal to 3 active disease sites (including primary tumour) amenable to local ablative therapy, as determined by investigator; At least one brain imaging (CT Brain or MRI Brain with contrast, preferably MRI Brain), either at time of diagnosis or while on osimertinib treatment but before randomization, to document CNS status for stratification. Patients with asymptomatic CNS metastases are eligible. For patients with brain metastases diagnosed at baseline, follow up brain imaging is recommended before randomization; Patients with history of palliative radiotherapy are eligible; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L; Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN; Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation; Willing and able to comply with the requirements and restrictions in this protocol.
Exclusion: Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical cancer in situ; Contraindication to radiotherapy; Any serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment related complications; Mixed SCLC and NSCLC histology; Positive pregnancy test.